SREK1

Summary

SREK1 (splicing regulatory glutamic acid and lysine rich protein 1, HGNC:17882) is a protein-coding gene on chromosome 5q12.3, encoding Splicing regulatory glutamine/lysine-rich protein 1 (Q8WXA9). Participates in the regulation of alternative splicing by modulating the activity of other splice facors. It is a selective cancer dependency (DepMap: 20.4% of cell lines).

This gene encodes a member of a family of serine/arginine-rich (SR) splicing proteins containing RNA recognition motif (RRM) domains. The encoded protein interacts with other SR proteins to modulate splice site selection. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 140890 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 77 total
• Cancer dependency (DepMap): dependent in 20.4% of screened cell lines
• MANE Select transcript: NM_001077199

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17882
Approved symbol	SREK1
Name	splicing regulatory glutamic acid and lysine rich protein 1
Location	5q12.3
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp564B176, SRrp86, SRrp508
Ensembl gene	ENSG00000153914
Ensembl biotype	protein_coding
OMIM	609268
Entrez	140890

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 11 protein_coding, 7 retained_intron, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000284041, ENST00000334121, ENST00000380918, ENST00000518110, ENST00000519205, ENST00000519259, ENST00000520058, ENST00000520580, ENST00000520953, ENST00000521691, ENST00000522214, ENST00000522912, ENST00000523655, ENST00000523851, ENST00000524111, ENST00000612404, ENST00000868036, ENST00000868037, ENST00000936174, ENST00000936175, ENST00000936176, ENST00000972139, ENST00000972140

RefSeq mRNA: 8 — MANE Select: NM_001077199 NM_001077199, NM_001270492, NM_001323527, NM_001323529, NM_001323533, NM_001323534, NM_001323535, NM_139168

CCDS: CCDS3991, CCDS43323

Canonical transcript exons

ENST00000334121 — 12 exons

Exon	Start	End
ENSE00001915889	66178719	66183615
ENSE00003470852	66153463	66153596
ENSE00003501668	66170585	66170947
ENSE00003511409	66174946	66175041
ENSE00003570860	66163792	66163922
ENSE00003579548	66164783	66164897
ENSE00003600897	66159219	66159334
ENSE00003616806	66170051	66170170
ENSE00003628677	66177514	66177658
ENSE00003665562	66162414	66162592
ENSE00003788419	66162109	66162273
ENSE00003843436	66144300	66144537

Expression profiles

Bgee: expression breadth ubiquitous, 298 present calls, max score 99.01.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 40.4813 / max 540.8552, expressed in 1818 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
56726	31.6107	1813
56725	8.7623	1686
56727	0.1083	30

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	99.01	gold quality
calcaneal tendon	UBERON:0003701	98.09	gold quality
right uterine tube	UBERON:0001302	96.62	gold quality
adrenal tissue	UBERON:0018303	96.53	gold quality
corpus epididymis	UBERON:0004359	96.36	gold quality
ventricular zone	UBERON:0003053	96.34	gold quality
caput epididymis	UBERON:0004358	96.33	gold quality
body of pancreas	UBERON:0001150	96.15	gold quality
left lobe of thyroid gland	UBERON:0001120	96.07	gold quality
metanephros cortex	UBERON:0010533	96.02	gold quality
right lobe of thyroid gland	UBERON:0001119	95.97	gold quality
thyroid gland	UBERON:0002046	95.86	gold quality
body of uterus	UBERON:0009853	95.79	gold quality
endometrium	UBERON:0001295	95.56	gold quality
mucosa of stomach	UBERON:0001199	95.49	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	95.40	gold quality
cauda epididymis	UBERON:0004360	95.15	gold quality
minor salivary gland	UBERON:0001830	95.13	gold quality
tibial nerve	UBERON:0001323	95.07	gold quality
colonic epithelium	UBERON:0000397	95.06	gold quality
choroid plexus epithelium	UBERON:0003911	95.00	gold quality
skin of abdomen	UBERON:0001416	94.93	gold quality
right ovary	UBERON:0002118	94.91	gold quality
endocervix	UBERON:0000458	94.83	gold quality
bronchial epithelial cell	CL:0002328	94.79	gold quality
seminal vesicle	UBERON:0000998	94.68	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.61	gold quality
upper leg skin	UBERON:0004262	94.58	gold quality
skin of hip	UBERON:0001554	94.57	gold quality
uterus	UBERON:0000995	94.53	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ENAD-17	no	1107.68
E-CURD-135	no	630.62
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

274 targeting SREK1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 20.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 7)

• SRrp86 can activate SRp20 and repress SC35 in a dose-dependent manner both in vitro and in vivo (PMID:11991645)
• the unique glutamic acid-lysine domain of SRrp86 plays a modulatory role controlling serine-arginine domain function (PMID:12183448)
• p18SRP is a lysine-rich zinc finger domain-containing protein that interacts with the serine-arginine-rich splicing regulatory protein SRrp86; it is downregulated in brain of Alzheimer disease patients. (PMID:15456940)
• From among the 500 splicing events exhibiting altered splicing under these conditions, the splicing of c-Jun and IkappaBbeta were validated as being regulated by SRrp86 resulting in altered regulation of their downstream targets. (PMID:20400856)
• Pathogenic SREK1 decrease in Huntington’s disease lowers TAF1 mimicking X-linked dystonia parkinsonism. (PMID:32533168)
• The rs74794265 SNP of the SREK1 Gene is Associated with COPD in Kashi, China. (PMID:34556983)
• The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma. (PMID:35296659)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	srek1	ENSDARG00000009764
rattus_norvegicus		ENSRNOG00000068845
drosophila_melanogaster	Srp54	FBGN0024285

Paralogs (1): SRSF11 (ENSG00000116754)

Protein

Protein identifiers

Splicing regulatory glutamine/lysine-rich protein 1 — Q8WXA9 (reviewed: Q8WXA9)

Alternative names: Serine/arginine-rich-splicing regulatory protein 86, Splicing factor, arginine/serine-rich 12, Splicing regulatory protein 508

All UniProt accessions (6): Q8WXA9, A0A087WY03, E5RFV3, E5RJ76, E5RK30, H0YC47

UniProt curated annotations — full annotation on UniProt →

Function. Participates in the regulation of alternative splicing by modulating the activity of other splice facors. Inhibits the splicing activity of SFRS1, SFRS2 and SFRS6. Augments the splicing activity of SFRS3.

Subunit / interactions. Homodimer. Binds SFRS1, SFRS2, SFRS3 and SFRS6. Interacts with the spliceosome. Interacts with SREK1IP1.

Subcellular location. Nucleus.

Similarity. Belongs to the splicing factor SR family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8WXA9-1	1	yes
Q8WXA9-2	2

RefSeq proteins (8): NP_001070667, NP_001257421, NP_001310456, NP_001310458, NP_001310462, NP_001310463, NP_001310464, NP_631907 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034192	SREK1_RRM2	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily

Pfam: PF00076

UniProt features (14 total): compositionally biased region 6, modified residue 3, chain 1, domain 1, cross-link 1, splice variant 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WXA9-F1	63.79	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 184, 363, 504, 171

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 298 (showing top): WENDT_COHESIN_TARGETS_UP, GGGACCA_MIR133A_MIR133B, E2F_Q4, E2F_Q4_01, RRAGTTGT_UNKNOWN, HNF3ALPHA_Q6, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, TACAATC_MIR508, FOXO1_01, GGCNKCCATNK_UNKNOWN, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, AACWWCAANK_UNKNOWN, GTGCCTT_MIR506, MARTINEZ_RB1_TARGETS_UP

GO Biological Process (2): mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (3): RNA binding (GO:0003723), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (4): nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681), nuclear speck (GO:0016607), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
binding	2
mRNA metabolic process	1
nucleic acid binding	1
nuclear lumen	1
cellular anatomical structure	1
nuclear protein-containing complex	1
ribonucleoprotein complex	1
nuclear ribonucleoprotein granule	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2070 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SREK1	SRSF3	P23152	841
SREK1	SREK1IP1	Q8N9Q2	786
SREK1	SRSF1	Q07955	660
SREK1	SRSF6	Q13247	650
SREK1	PNISR	Q8TF01	508
SREK1	DDX46	Q7L014	500
SREK1	LUC7L3	O95232	493
SREK1	A0A1B0GW23	A0A1B0GW23	479
SREK1	PRPF40A	O75400	476
SREK1	SRSF4	Q08170	456
SREK1	SFSWAP	Q12872	448
SREK1	PRPF39	Q86UA1	448
SREK1	ZNF572	Q7Z3I7	435
SREK1	CREG2	Q8IUH2	418
SREK1	LRRC40	Q9H9A6	414

IntAct

145 interactions, top by confidence:

A	B	Type	Score
SREK1	SRPK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.760
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
SNRPA1	U2SURP	psi-mi:“MI:0914”(association)	0.640
ZRANB2	PIP4K2A	psi-mi:“MI:0914”(association)	0.610
NPM1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.610
SREK1	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.590
SRSF11	SREK1	psi-mi:“MI:0915”(physical association)	0.560
SREK1	SRSF11	psi-mi:“MI:0915”(physical association)	0.560
RBM39	SREK1	psi-mi:“MI:0915”(physical association)	0.560
SREK1	GPRASP2	psi-mi:“MI:0915”(physical association)	0.560
TXLNA	SREK1	psi-mi:“MI:0915”(physical association)	0.560
PRPF40A	SREK1	psi-mi:“MI:0915”(physical association)	0.560
ARL6IP4	SREK1	psi-mi:“MI:0915”(physical association)	0.560
RPS3	ZNF316	psi-mi:“MI:0914”(association)	0.530
H1-6	ZNF724	psi-mi:“MI:0914”(association)	0.530
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
PAIP2B	CASC3	psi-mi:“MI:0914”(association)	0.530
SRPK2	RRP9	psi-mi:“MI:0914”(association)	0.530
NIFK	RSL1D1	psi-mi:“MI:0914”(association)	0.530
SNRPC	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
RPS2	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
ABT1	ZNF316	psi-mi:“MI:0914”(association)	0.530
SRSF5	CBX6	psi-mi:“MI:0914”(association)	0.530
SREK1	SREK1	psi-mi:“MI:0915”(physical association)	0.370
CEP290	SUPT5H	psi-mi:“MI:0914”(association)	0.350
CEP135	AIMP1	psi-mi:“MI:0914”(association)	0.350
SSX2IP	IPO7	psi-mi:“MI:0914”(association)	0.350

BioGRID (251): SREK1 (Two-hybrid), SREK1 (Two-hybrid), SREK1 (Affinity Capture-MS), SREK1 (Affinity Capture-MS), SREK1 (Affinity Capture-MS), SREK1 (Affinity Capture-MS), PNN (Affinity Capture-MS), RNPS1 (Affinity Capture-MS), JMJD6 (Affinity Capture-MS), SRSF8 (Affinity Capture-MS), SRSF10 (Affinity Capture-MS), PUF60 (Co-fractionation), SREK1 (Co-fractionation), SREK1 (Co-fractionation), SREK1 (Co-fractionation)

ESM2 similar proteins: A0JNI5, A2AJT4, D3ZTQ1, O35691, O75376, P79149, Q05519, Q12872, Q14241, Q149C2, Q3USH5, Q4KKX4, Q4R6F6, Q53F19, Q568R1, Q569Z6, Q5BJ39, Q5BL56, Q5HZB6, Q5M7V8, Q5R5X0, Q5SFM8, Q5T8P6, Q5ZM19, Q60974, Q63187, Q6DFQ2, Q6NZN0, Q6PJT7, Q6WKW9, Q6ZPZ3, Q8BZR9, Q8BZX4, Q8CB77, Q8CFC7, Q8K019, Q8K3W3, Q8K3X0, Q8N2M8, Q8QG78

Diamond homologs: A0A0D1C8Z4, A2Q848, A6NDY0, A8WLV5, B0BNE4, B3LYP1, B3P0D7, B4JUT1, B4KCD5, B4LZ88, O13620, O13741, O13845, O14327, O80678, P19683, P19684, P20397, P33240, P38922, P40561, P42696, P49313, P49314, Q00916, Q05AT9, Q05CL8, Q06106, Q08208, Q08937, Q09295, Q09301, Q10B98, Q1PEP5, Q28165, Q28ZX3, Q44554, Q44556, Q44560, Q4G0J3

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 133 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	8	33.8×	1e-09
Eukaryotic Translation Initiation	8	27.4×	5e-09
Cap-dependent Translation Initiation	8	27.4×	5e-09
SARS-CoV-1 modulates host translation machinery	8	27.4×	5e-09
Nonsense-Mediated Decay (NMD)	10	25.9×	7e-11
Eukaryotic Translation Elongation	8	24.8×	1e-08
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	8	24.2×	1e-08
Peptide chain elongation	16	22.6×	5e-16

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	7	44.3×	2e-08
regulation of mRNA splicing, via spliceosome	6	44.0×	3e-07
mRNA splice site recognition	5	33.2×	2e-05
cytoplasmic translation	18	27.6×	1e-18
regulation of alternative mRNA splicing, via spliceosome	9	18.2×	2e-07
RNA processing	9	16.3×	3e-07
ribosomal small subunit biogenesis	8	15.1×	4e-06
negative regulation of translation	9	14.6×	8e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	68
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2459 predictions. Top by Δscore:

Variant	Effect	Δscore
5:66144533:CCGGA:C	donor_gain	1.0000
5:66144534:CGGA:C	donor_gain	1.0000
5:66144535:GGA:G	donor_gain	1.0000
5:66144535:GGAG:G	donor_gain	1.0000
5:66144536:GA:G	donor_gain	1.0000
5:66144536:GAG:G	donor_gain	1.0000
5:66144537:AGTA:A	donor_loss	1.0000
5:66144538:G:GG	donor_gain	1.0000
5:66144538:GTAA:G	donor_loss	1.0000
5:66146747:T:TA	donor_gain	1.0000
5:66146748:AGT:A	donor_gain	1.0000
5:66153462:GCAAC:G	acceptor_gain	1.0000
5:66153593:GAAG:G	donor_gain	1.0000
5:66154234:GCCT:G	donor_gain	1.0000
5:66159214:TGCA:T	acceptor_loss	1.0000
5:66159216:CA:C	acceptor_loss	1.0000
5:66159218:G:A	acceptor_loss	1.0000
5:66159218:GGT:G	acceptor_gain	1.0000
5:66159218:GGTA:G	acceptor_gain	1.0000
5:66159218:GGTAA:G	acceptor_gain	1.0000
5:66159330:CTACT:C	donor_gain	1.0000
5:66159331:TACT:T	donor_gain	1.0000
5:66159332:ACT:A	donor_gain	1.0000
5:66159332:ACTGT:A	donor_loss	1.0000
5:66159333:CT:C	donor_gain	1.0000
5:66159334:TG:T	donor_loss	1.0000
5:66159335:G:GG	donor_gain	1.0000
5:66159336:TAAG:T	donor_loss	1.0000
5:66159337:AAGTA:A	donor_loss	1.0000
5:66162103:C:A	acceptor_gain	1.0000

AlphaMissense

4098 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:66162223:A:G	K60E	1.000
5:66162225:A:C	K60N	1.000
5:66162225:A:T	K60N	1.000
5:66162232:G:A	E63K	1.000
5:66162235:A:T	I64F	1.000
5:66162236:T:A	I64N	1.000
5:66162236:T:C	I64T	1.000
5:66162236:T:G	I64S	1.000
5:66162242:G:C	R66T	1.000
5:66162242:G:T	R66I	1.000
5:66162243:A:C	R66S	1.000
5:66162243:A:T	R66S	1.000
5:66162244:A:C	T67P	1.000
5:66162244:A:G	T67A	1.000
5:66162245:C:A	T67K	1.000
5:66162245:C:G	T67R	1.000
5:66162245:C:T	T67M	1.000
5:66162248:T:A	V68D	1.000
5:66162250:T:A	Y69N	1.000
5:66162250:T:C	Y69H	1.000
5:66162250:T:G	Y69D	1.000
5:66162251:A:G	Y69C	1.000
5:66162253:G:T	V70F	1.000
5:66162254:T:A	V70D	1.000
5:66162256:G:A	G71R	1.000
5:66162256:G:C	G71R	1.000
5:66162257:G:A	G71E	1.000
5:66162257:G:C	G71A	1.000
5:66162257:G:T	G71V	1.000
5:66162259:A:C	N72H	1.000

dbSNP variants (sampled 300 via entrez): RS1000119510 (5:66183898 T>C), RS1000308615 (5:66145182 G>A,T), RS1000317316 (5:66166304 T>C), RS1000320648 (5:66174580 T>C), RS1000353307 (5:66156862 C>T), RS1000394464 (5:66174135 A>G,T), RS1000444859 (5:66144977 C>G,T), RS1000483434 (5:66181782 C>A,G), RS1000569406 (5:66168310 T>G), RS1000683161 (5:66183351 A>G), RS1000726395 (5:66161806 T>G), RS1000755222 (5:66183594 A>G), RS1000767166 (5:66144008 C>T), RS1000800064 (5:66161629 C>G,T), RS1000818786 (5:66149128 C>G,T)

Disease associations

OMIM: gene MIM:609268 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST006624_85	Systolic blood pressure	2.000000e-09
GCST007000_2	Logical memory (delayed recall) in mild cognitive impairment	8.000000e-07
GCST009391_858	Metabolite levels	4.000000e-06
GCST009391_99	Metabolite levels	7.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0004874	memory performance
EFO:0010533	sorbitol measurement
EFO:0010473	cyclic adenosine monophosphate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	6
methylmercuric chloride	increases expression	2
methacrylaldehyde	increases abundance, affects cotreatment, decreases expression, increases oxidation	2
Acrolein	decreases expression, increases oxidation, increases abundance, affects cotreatment	2
Ozone	affects cotreatment, decreases expression, increases oxidation, increases abundance	2
aristolochic acid I	decreases expression	1
TAK-243	decreases sumoylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
methylparaben	increases expression	1
perfluorodecanoic acid	increases expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
torcetrapib	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	decreases expression	1
Air Pollutants	increases oxidation, affects cotreatment, decreases expression, increases abundance	1
Benztropine	decreases expression	1
Cadmium	decreases expression	1
Caffeine	increases phosphorylation	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Estradiol	affects expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.